CINCINNATI--(BUSINESS WIRE)--Mar. 20, 2012--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), was founded in London, UK in 1992 by
Marco Calzavara, President of Meridian Bioscience Europe. Bioline is a
leading manufacturer and distributor of PCR enzymes and molecular
biology reagents providing complete solutions to researchers in
universities, major research institutions, hospitals, biotech and
pharmaceutical firms in virtually every corner of the world.
Bioline’s core strength is its long experience and extensive know-how in
PCR and real-time PCR enzymes technology. The PCR reagents portfolio
includes all components required for PCR and real-time PCR: DNA
polymerases and master mixes, reverse transcriptases, nucleotides,
buffers and additives. Bioline’s PCR and real-time PCR products are
thoroughly validated with all the major instrument systems on the market.
Marco Calzavara, President of Meridian Bioscience Europe, commented,
“Our aim at Bioline for the past 20 years has been to develop
high-quality and reliable products that make the difference, delivering
consistent results time after time. I am excited to carry on Bioline’s
great work as a cutting edge molecular biology company, ensuring that we
maintain our reputation as a high-quality and reliable firm.”
Richard L. Eberly, Chief Commercial Officer of Meridian Bioscience,
Inc., stated, “Congratulations to the Bioline team on its 20th
anniversary of successful operations throughout the world. We are
enthusiastic about the success of the merger and impressed by the
scientific capabilities of Bioline, as well as, its well-deserved
reputation for innovation and quality. We remain committed to expanding
the rapidly growing portfolio of highly specialized molecular biology
products from Bioline that enable the development of genomic tests
utilized by researchers, clinical diagnostic laboratories, diagnostic
test manufacturers and biotechnology companies.”
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that manufactures,
markets and distributes a broad range of innovative diagnostic test
kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company’s products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
veterinary testing centers, diagnostics manufacturers and biotech
companies in more than 60 countries around the world. The Company’s
shares are traded through NASDAQ’s Global Select Market, symbol VIVO.
Meridian’s website address is www.meridianbioscience.com.
For more information about Bioline, please visit www.bioline.com/20
For more information about Meridian Life Science, Inc.,
please visit www.meridianlifescience.com.
more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com.
L. Eberly, Chief Commercial Officer, firstname.lastname@example.org
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
Richard L. Eberly, Chief Commercial